40
Participants
Start Date
September 2, 2020
Primary Completion Date
September 30, 2024
Study Completion Date
September 30, 2024
L19IL2 +L19TNF
Single or multiple intratumoral administration of a mixture of L19IL2 and L19TNF will be performed once weekly for up to 4 weeks into all injectable lesions present at the beginning of treatment or appearing during treatment phase The dose will be constituted by 6.5 Mio IU L19IL2 (\~1.08 mg) and 200 µg L19TNF.
RECRUITING
Universitätsspital Zürich (USZ), Zurich
RECRUITING
Charité Universitätsmedizin Berlin, Berlin
RECRUITING
University Medical Center Schleswig Holstein, Kiel
RECRUITING
Universitätsklinikum Essen (AöR), Essen
RECRUITING
Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg
RECRUITING
Universitätsklinikum Augsburg, Augsburg
RECRUITING
Universitätsklinikum Regensburg, Regensburg
NOT_YET_RECRUITING
University Hospital Carl Gustav Carus, Dresden
RECRUITING
Tübingen University Hospital, Tübingen
RECRUITING
Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie Warszawa, Warsaw
RECRUITING
Kantonsspital St.Gallen, Clinical Trials Unit, Dermatologie und Venerologie, Sankt Gallen
Philogen S.p.A.
INDUSTRY